MedTrace Logo

Long-term Outcomes of Prostate Cancer Screening

NCT07155759 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7500

Last updated 2025-09-04

No results posted yet for this study

Summary

This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and randomized to a screening program using PSA, a biomarker test and MRI; (ii) invited and randomized to a single PSA test with prostate biopsies followed by opportunistic testing and (iii) population controls. Mortality is verified through register data, disease verification is made through in-study biopsy results and registry data.

Conditions

Interventions

DIAGNOSTIC_TEST

PSA/Stockholm3/MRI

Stockholm3+PSA followed by MRI of the prostate

DIAGNOSTIC_TEST

PSA

PSA followed by standard biopsies

Sponsors & Collaborators

  • Swedish Cancer Foundation

    collaborator OTHER

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Tobias Nordström, Ass Prof · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
74 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-10-01
Completion
2035-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07155759 on ClinicalTrials.gov